Literature DB >> 25784504

Neuronal identity genes regulated by super-enhancers are preferentially down-regulated in the striatum of Huntington's disease mice.

Mayada Achour1, Stéphanie Le Gras2, Céline Keime2, Frédéric Parmentier3, François-Xavier Lejeune3, Anne-Laurence Boutillier4, Christian Néri3, Irwin Davidson5, Karine Merienne6.   

Abstract

Huntington's disease (HD) is a neurodegenerative disease associated with extensive down-regulation of genes controlling neuronal function, particularly in the striatum. Whether altered epigenetic regulation underlies transcriptional defects in HD is unclear. Integrating RNA-sequencing (RNA-seq) and chromatin-immunoprecipitation followed by massively parallel sequencing (ChIP-seq), we show that down-regulated genes in HD mouse striatum associate with selective decrease in H3K27ac, a mark of active enhancers, and RNA Polymerase II (RNAPII). In addition, we reveal that decreased genes in HD mouse striatum display a specific epigenetic signature, characterized by high levels and broad patterns of H3K27ac and RNAPII. Our results indicate that this signature is that of super-enhancers, a category of broad enhancers regulating genes defining tissue identity and function. Specifically, we reveal that striatal super-enhancers display extensive H3K27 acetylation within gene bodies, drive transcription characterized by low levels of paused RNAPII, regulate neuronal function genes and are enriched in binding motifs for Gata transcription factors, such as Gata2 regulating striatal identity genes. Together, our results provide evidence for preferential down-regulation of genes controlled by super-enhancers in HD striatum and indicate that enhancer topography is a major parameter determining the propensity of a gene to be deregulated in a neurodegenerative disease.
© The Author 2015. Published by Oxford University Press. All rights reserved. For Permissions, please email: journals.permissions@oup.com.

Entities:  

Mesh:

Substances:

Year:  2015        PMID: 25784504     DOI: 10.1093/hmg/ddv099

Source DB:  PubMed          Journal:  Hum Mol Genet        ISSN: 0964-6906            Impact factor:   6.150


  38 in total

Review 1.  Lingering Questions about Enhancer RNA and Enhancer Transcription-Coupled Genomic Instability.

Authors:  Gerson Rothschild; Uttiya Basu
Journal:  Trends Genet       Date:  2017-01-10       Impact factor: 11.639

Review 2.  Dissecting Tissue-Specific Super-Enhancers by Integrating Genome-Wide Analyses and CRISPR/Cas9 Genome Editing.

Authors:  Kyung Hyun Yoo; Lothar Hennighausen; Ha Youn Shin
Journal:  J Mammary Gland Biol Neoplasia       Date:  2018-10-06       Impact factor: 2.673

3.  Developmental alterations in Huntington's disease neural cells and pharmacological rescue in cells and mice.

Authors: 
Journal:  Nat Neurosci       Date:  2017-03-20       Impact factor: 24.884

4.  Treatment with JQ1, a BET bromodomain inhibitor, is selectively detrimental to R6/2 Huntington's disease mice.

Authors:  Amanda J Kedaigle; Jack C Reidling; Ryan G Lim; Miriam Adam; Jie Wu; Brook Wassie; Jennifer T Stocksdale; Malcolm S Casale; Ernest Fraenkel; Leslie M Thompson
Journal:  Hum Mol Genet       Date:  2020-01-15       Impact factor: 6.150

5.  Linking epigenetic dysregulation, mitochondrial impairment, and metabolic dysfunction in SBMA motor neurons.

Authors:  Naemeh Pourshafie; Ester Masati; Eric Bunker; Alec R Nickolls; Parisorn Thepmankorn; Kory Johnson; Xia Feng; Tyler Ekins; Christopher Grunseich; Kenneth H Fischbeck
Journal:  JCI Insight       Date:  2020-07-09

Review 6.  Molecular Targets and Therapeutic Strategies in Spinocerebellar Ataxia Type 7.

Authors:  Anna Niewiadomska-Cimicka; Yvon Trottier
Journal:  Neurotherapeutics       Date:  2019-10       Impact factor: 7.620

Review 7.  The structural and functional roles of CTCF in the regulation of cell type-specific and human disease-associated super-enhancers.

Authors:  Ha Youn Shin
Journal:  Genes Genomics       Date:  2018-11-19       Impact factor: 1.839

8.  Postnatal and adult consequences of loss of huntingtin during development: Implications for Huntington's disease.

Authors:  Eduardo E Arteaga-Bracho; Maria Gulinello; Michael L Winchester; Nandini Pichamoorthy; Jenna R Petronglo; Alicia D Zambrano; Julio Inocencio; Chirstopher D De Jesus; Joseph O Louie; Solen Gokhan; Mark F Mehler; Aldrin E Molero
Journal:  Neurobiol Dis       Date:  2016-09-10       Impact factor: 5.996

Review 9.  Epigenetics and therapeutic targets mediating neuroprotection.

Authors:  Irfan A Qureshi; Mark F Mehler
Journal:  Brain Res       Date:  2015-07-30       Impact factor: 3.252

10.  Improved Protocol for Chromatin Immunoprecipitation from Mouse Skeletal Muscle.

Authors:  Shilpy Joshi; Vanessa Ueberschlag-Pitiot; Daniel Metzger; Irwin Davidson
Journal:  J Vis Exp       Date:  2017-11-06       Impact factor: 1.355

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.